76 related articles for article (PubMed ID: 712208)
1. Effects of glucocorticoids on osteoclast-activating factor.
Strumpf M; Kowalski MA; Mundy GR
J Lab Clin Med; 1978 Nov; 92(5):772-8. PubMed ID: 712208
[TBL] [Abstract][Full Text] [Related]
2. Big and little forms of osteoclast activating factor.
Mundy GR; Raisz LG; Shapiro JL; Bandelin JG; Turcotte RJ
J Clin Invest; 1977 Jul; 60(1):122-8. PubMed ID: 874077
[TBL] [Abstract][Full Text] [Related]
3. Partial purification of osteoclast-activating factor from phytohemagglutinin-stimulated human leukocytes.
Luben RA; Mundy GR; Trummel CL; Raisz LG
J Clin Invest; 1974 May; 53(5):1473-80. PubMed ID: 4825237
[TBL] [Abstract][Full Text] [Related]
4. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
Torcia M; Lucibello M; Vannier E; Fabiani S; Miliani A; Guidi G; Spada O; Dower SK; Sims JE; Shaw AR; Dinarello CA; Garaci E; Cozzolino F
Exp Hematol; 1996 Jul; 24(8):868-74. PubMed ID: 8690044
[TBL] [Abstract][Full Text] [Related]
5. Observations on the mechanism of bone resorption induced by multiple myeloma marrow culture fluids and partially purified osteoclast-activating factor.
Josse RG; Murray TM; Mundy GR; Jez D; Heersche JN
J Clin Invest; 1981 May; 67(5):1472-81. PubMed ID: 6262378
[TBL] [Abstract][Full Text] [Related]
6. Effect of osteoclast activating factor from human leukocytes on bone metabolism.
Raisz LG; Luben RA; Mundy GR; Dietrich JW; Horton JE; Trummel CL
J Clin Invest; 1975 Aug; 56(2):408-13. PubMed ID: 1171115
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapy.
Mundy GR; Rick ME; Turcotte R; Kowalski MA
Am J Med; 1978 Oct; 65(4):600-6. PubMed ID: 707520
[TBL] [Abstract][Full Text] [Related]
8. [The effects of osteoclast-activating factor (OAF) on the absorption of alveolar bone. 1. Production and purification of OAF (author's transl)].
Marumoto Y; Kusunoki K; Fijihashi H; Osaka H; Nakamura Y; Ikeda K
Nihon Shishubyo Gakkai Kaishi; 1982 Mar; 24(1):121-7. PubMed ID: 6980245
[No Abstract] [Full Text] [Related]
9. Release of osteoclast activating factor by normal human peripheral blood leukocytes.
Trummel CL; Mundy GR; Raisz LG
J Lab Clin Med; 1975 Jun; 85(6):1001-7. PubMed ID: 1138018
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandins are necessary for osteoclast-activating factor production by activated peripheral blood leukocytes.
Yoneda T; Mundy GR
J Exp Med; 1979 Jan; 149(1):279-83. PubMed ID: 105076
[TBL] [Abstract][Full Text] [Related]
11. Production of osteoclast-activating factor by normal human peripheral blood rosetting and nonrosetting lymphocytes.
Chen P; Trummel C; Horton J; Baker JJ; Oppenheim JJ
Eur J Immunol; 1976 Oct; 6(10):732-6. PubMed ID: 797286
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo.
Uy HL; Mundy GR; Boyce BF; Story BM; Dunstan CR; Yin JJ; Roodman GD; Guise TA
Cancer Res; 1997 Aug; 57(15):3194-9. PubMed ID: 9242449
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoids impair bone resorptive activity and viability of osteoclasts disaggregated from neonatal rat long bones.
Tobias J; Chambers TJ
Endocrinology; 1989 Sep; 125(3):1290-5. PubMed ID: 2759026
[TBL] [Abstract][Full Text] [Related]
14. Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma.
Durie BG; Salmon SE; Mundy GR
Br J Haematol; 1981 Jan; 47(1):21-30. PubMed ID: 7437344
[TBL] [Abstract][Full Text] [Related]
15. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity.
Pederson L; Winding B; Foged NT; Spelsberg TC; Oursler MJ
Cancer Res; 1999 Nov; 59(22):5849-55. PubMed ID: 10582709
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
[TBL] [Abstract][Full Text] [Related]
17. Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro.
Gowen M; Mundy GR
J Immunol; 1986 Apr; 136(7):2478-82. PubMed ID: 3081643
[TBL] [Abstract][Full Text] [Related]
18. [Hypercalcemia in multiple myeloma].
Takahashi T
Nihon Rinsho; 1995 Mar; 53(3):710-4. PubMed ID: 7699910
[TBL] [Abstract][Full Text] [Related]
19. [Immunologic mechanisms of regulating calcium metabolism in human bone tissue (production of osteoclast-activating factor) during long-term anti-orthostatic hypokinesia].
Konstantinova IV; Lesniak AT; Bozhikov NV; Uchakin PN
Kosm Biol Aviakosm Med; 1989; 23(3):38-42. PubMed ID: 2788231
[TBL] [Abstract][Full Text] [Related]
20. Antithetic effects of ryanodine and ruthenium red on osteoclast-mediated bone resorption and intracellular calcium concentrations.
Ritchie CK; Strei TA; Maercklein PB; Fitzpatrick LA
J Cell Biochem; 1995 Oct; 59(2):281-9. PubMed ID: 8904321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
